Trials / Completed
CompletedNCT06703268
A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients
A Multicenter, Randomized, Open-label, Controlled Study on Evaluating the Efficacy and Safety of Switching From Daily DPP-4 Inhibitors to HSK7653 Tablets in Patients With Type 2 Diabetes Mellitus in China
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effectiveness of HSK7653 tablets following the substitution of daily DPP-4 inhibitor (DPP-4i) over a 24-week treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK7653 10 mg | HSK7653 10 mg Q2W |
| DRUG | Daily DPP-4 inhibitor | Daily DPP-4 inhibitor |
Timeline
- Start date
- 2024-01-15
- Primary completion
- 2024-10-05
- Completion
- 2024-11-20
- First posted
- 2024-11-25
- Last updated
- 2024-11-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06703268. Inclusion in this directory is not an endorsement.